PT966301E - Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i - Google Patents

Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i

Info

Publication number
PT966301E
PT966301E PT97936334T PT97936334T PT966301E PT 966301 E PT966301 E PT 966301E PT 97936334 T PT97936334 T PT 97936334T PT 97936334 T PT97936334 T PT 97936334T PT 966301 E PT966301 E PT 966301E
Authority
PT
Portugal
Prior art keywords
class
identification
mhc
heavy chain
genes involved
Prior art date
Application number
PT97936334T
Other languages
English (en)
Inventor
Klaus Frueh
Young Yang
Kwangseog Ahn
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of PT966301E publication Critical patent/PT966301E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
PT97936334T 1996-07-31 1997-07-31 Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i PT966301E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2284796P 1996-07-31 1996-07-31
US4621397P 1997-05-12 1997-05-12

Publications (1)

Publication Number Publication Date
PT966301E true PT966301E (pt) 2005-06-30

Family

ID=26696435

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97936334T PT966301E (pt) 1996-07-31 1997-07-31 Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i

Country Status (8)

Country Link
US (1) US6033671A (pt)
EP (1) EP0966301B1 (pt)
AT (1) ATE288764T1 (pt)
AU (1) AU730351B2 (pt)
DE (1) DE69732498T2 (pt)
ES (1) ES2237800T3 (pt)
PT (1) PT966301E (pt)
WO (1) WO1998004285A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047914A2 (de) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Us6 gen aus dem humanen cytomegalovirus (hcmv)
CA2437201C (en) * 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US7264814B2 (en) * 2001-05-09 2007-09-04 M's Science Corporation Composition and method for treating cancer using herpes virus
EP3187585A1 (en) * 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
LT3333265T (lt) 2010-05-14 2020-05-25 Oregon Health & Science University Rekombinantiniai žcmv ir rhcmv vektoriai, koduojantys heterologinį antigeną, išskirtą iš hepatito b viruso, ir jų panaudojimas
US20120020885A1 (en) * 2010-07-26 2012-01-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware MHC-Less cells
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
JP6483033B2 (ja) 2013-03-05 2019-03-13 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティＯｒｅｇｏｎ Ｈｅａｌｔｈ ＆ Ｓｃｉｅｎｃｅ Ｕｎｉｖｅｒｓｉｔｙ Ｔ細胞ターゲティングを調節することができるサイトメガロウイルスベクター
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
CN107002048B (zh) 2014-07-16 2021-07-06 俄勒冈健康与科学大学 包含外源抗原的人巨细胞病毒
EP3256595A4 (en) 2015-02-10 2018-09-26 Oregon Health & Science University Methods and compositions useful in generating non canonical cd8+ t cell responses
MA43285A (fr) 2015-11-20 2018-09-26 Univ Oregon Health & Science Vecteurs cmv comprenant des éléments de reconnaissance des microarn
CA3028827A1 (en) 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
MX2019004518A (es) 2016-10-18 2019-06-17 Univ Oregon Health & Science Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e.
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877004A (en) * 1991-07-05 1999-03-02 American Cyanamid Compound Human cytomegalovirus containing a β-glucuronidase marker gene
US5846806A (en) * 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
WO1998047914A2 (de) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Us6 gen aus dem humanen cytomegalovirus (hcmv)

Also Published As

Publication number Publication date
DE69732498D1 (de) 2005-03-17
EP0966301B1 (en) 2005-02-09
AU730351B2 (en) 2001-03-08
ES2237800T3 (es) 2005-08-01
US6033671A (en) 2000-03-07
EP0966301A1 (en) 1999-12-29
AU3903297A (en) 1998-02-20
WO1998004285A1 (en) 1998-02-05
EP0966301A4 (en) 2001-09-05
ATE288764T1 (de) 2005-02-15
DE69732498T2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
PT966301E (pt) Identificacao de genes do citomegalovirus humano envolvidos na regulacao negativa da expressao da cadeia pesada do mhc classe i
Riddell et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
Andersson et al. Reduced allorecognition of adenovirus-2 infected cells.
Lenschow et al. Expression and functional significance of an additional ligand for CTLA-4.
US6361770B1 (en) Method of enhancing expression of MHC class I molecules bearing endogenous peptides
Koszinowski et al. The role of CD4 and CD8 T cells in viral infections
GR3017915T3 (en) Antigens composed of "major histocompatibility complex" class I antigens and specific carrier molecules, their production and use.
Salem et al. In vivo acute depletion of CD8+ T cells before murine cytomegalovirus infection upregulated innate antiviral activity of natural killer cells
CA2165458A1 (fr) Proteines intracellulaires de liaison (pil) et leurs utilisations
Davis et al. Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells
Toomey et al. MHC class I expression protects target cells from lysis by Ly49‐deficient fetal NK cells
Koh et al. Human CD8+ T-cell populations that express natural killer receptors
Smeland et al. Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells.
Abed et al. T cell-independent and T cell-dependent B cell activation increases IFN-gamma R expression and renders B cells sensitive to IFN-gamma-mediated inhibition.
US20030118568A1 (en) Viral stealth technology to prevent T cell-mediated rejection of xenografts
Shamsi et al. Short term exercise training enhances cell-mediated responses to HSV-1 vaccine in mice
Busch et al. MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies—a tool for decreased immunogenicity of allogeneic tissue and cell transplants
Duksin et al. Differential cytotoxic activity of anticollagen serum on rat osteoblasts and fibroblasts in tissue culture
Wesch et al. Differential expression of natural killer receptors on Vδ1 γδ T cells in HIV-1-infected individuals
Bagriacik et al. CD43 potentiates CD3‐induced proliferation of murine intestinal intraepithelial lymphocytes
KR980009278A (ko) 사람 파필로마 바이러스 18형 e6 단백질에 대한 인체의 면역성 조절기능을 갖는 펩타이드
KR0166425B1 (ko) 한탄 바이러스에 대한 인체 면역조절기능을 가진 펩타이드
Moller et al. IgA and rheumatoid factor in ankylosing spondylitis
Hänsch et al. The pathogenesis of ANCA-associated vasculitides: old hypotheses and new insights.
Spencer et al. Know thyself: variations in self peptidomes and their immunologic consequences